Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing.
BACKGROUND
Screening for hepatitis C has been found to be beneficial in high-risk individuals and 'baby boomers'.


OBJECTIVE
Our aim was to screen for hepatitis C in average and high-risk individuals and compare the disease characteristics and response to treatment among the screened group (SG) and non-screened group (NSG).


METHODS
Community-based screening for hepatitis C was done in the average and high-risk populations of Qatar. Screening was done using rapid point-of-care testing. All patients with stage 1 fibrosis on liver biopsy were treated with pegylated interferon and ribavirin.


RESULTS
In total, 13,704 people were screened and 272 (2%, 95% CI (1.8-2.2%) had positive antibodies to hepatitis C. During the same period, 237 non-screened patients (NSG) with hepatitis C were referred for treatment. Alanine and aspartate aminotransferases (ALT, AST) and overall fibrosis were significantly lower in the SG as compared with the NSG (p = 0.04, 0.04 and 0.01, respectively). The response to treatment was similar in the SG as compared with the NSG (sustained viral response 61.7 % versus 69.1%, p = 0.55). Average-risk patients had significantly lower ALT levels (p = 0.04) but had similar response to treatment as the high-risk individuals (sustained viral response 63.2 % versus 61%, p = 0.87).


CONCLUSIONS
Screening detects hepatitis C with lesser fibrosis but does not result in better response to pegylated interferon and ribavirin as compared with non-screened patients.
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Manik
M
Sharma
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Saad
S
Al Kaabi
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Anil K
AK
John
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Nazeeh
N
Al Dweik
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Hameed
H
Ullah Wani
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Ragesh
R
Babu Thandassary
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Moutaz F
MF
Derbala
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Khalid
K
Al Ejji
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Khaleel
K
Sultan
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Fuad
F
Pasic
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Munnera
M
Al Mohannadi
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Rafae
R
Yacoub
Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Mohd Tariq
MT
Butt
Department of CCS, Hamad Medical Corporation, Doha, Qatar.
Rajvir
R
Singh
Qatar; Screening; fibrosis; hepatitis C; treatment